AprèsFlex® 5-Day Joint Support

Three Gold Standard Human Clinical Trials

AprèsFlex has been the subject of seven pre-clinical and three human clinical studies. In the newest clinical study, Karlapudi and colleagues examined the efficacy of AprèsFlex in the management of joint comfort and function in a randomized, double-blind, placebo clinical trial. Sixty-seven subjects received either 100 mg/day of AprèsFlex or a matching placebo for thirty days.

Measurements included:

• Visual Analog Score (VAS)  (Graph A)
• The Lequesne algofunctional index (LFI)  (Graph B)
• The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (Graph C/D/E)  
• Serum biomarkers (MMP3, TNF, hsCRP, COMP, CPII and C2C)

Measurements were done on Days 0, 5 and 30.

The study showed that AprèsFlex:

-Provided significant reduction (p<0.05) in all the pain scores at five days compared to the placebo.
-Provided significant reduction (p<0.05) in all function scores at five days compared to placebo.

Post-trial, VAS, LFI, WOMAC pain, WOMAC stiffness, WOMAC function, and total WOMAC scores decreased in the AprèsFlex group by 45%, 40.9%, 44.4%, 66.3%, 44.4%, and 48%, respectively.

Beyond joint comfort and function improvements, AprèsFlex was also shown to offer statistically significant impact on biological markers associated with joint health and inflammation metabolism, including TNF-alpha, C-Reactive Protein (CRP), and Interleukin-6 (IL-6). It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), an enzyme that breaks down cartilage, collagen, and connective tissue.

Previous studies with AprèsFlex showed 56% reduction in pain scores at 30 days. A similar study with AprèsFlex showed a 69% reduction in pain scores at 90 days.

Safety Studies

In Sprague Dawley rats, acute oral LD50 of AprèsFlex was determined to be > 5000 mg/kg. Acute dermal LD50 was > 2000 mg/kg. No changes in body weight or adverse effects were observed. In a subacute 28-day repeat dose toxicity study, the NOAEL was determined to be > 2500 mg/kg. No abnormal changes related to the study product were demonstrated in hematology, clinical chemistry, or histopathology. No adverse effects were observed.

For more information on AprèsFlex science, see the Resources section below.

PLT Mobility Solutions

At PLT, we are working on the concept of Mobility Solutions – making these solutions available for people of all ages and walks of life. We’re thinking about athletes who want to perform better and recover faster. We’re thinking about people who have physically demanding jobs who don’t want to or can’t take a day off from work. We’re thinking about anyone who has an active lifestyle who wants to embrace it in spite of the rigors. And yes, we’re thinking about the global aging population.

PLT Health Solutions’ leading portfolio of mobility support ingredients – based on more than a decade of ongoing research – has been developed to help you deliver innovative products that can capture the attention and the trust of consumers. All of our ingredients are backed by multiple clinical studies – and offer rapid improvements from a low dose – in just about any delivery system you can imagine.